Home
Home About Us Our Technology News + Media Investor Relations Contact Us
 
Company Press Releases Publications








































































 

Company Press Releases                                                                               Back


CytoSorbents To Present at OneMedForum 2015 and Exhibit at the 44th Society of Critical Care Medicine Congress

Wednesday January 7, 2015

MONMOUTH JUNCTION, N.J., Jan. 7, 2015 - CytoSorbents Corporation (NASDAQ CM: CTSO), a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced that Dr. Phillip Chan, Chief Executive Officer, will present at the OneMedForum 2015 conference on Monday, January 12, 2015 at 2:00PM PST in the Marriott Marquis Hotel in San Francisco, California. A copy of the presentation will be posted to the Company's website following the conference. The conference is run concurrently with, but independently from, the 33rd Annual JP Morgan Healthcare Conference in San Francisco (January 12-15, 2015), one of the largest and most influential international healthcare conferences. During the conference, Dr. Chan will be joined by Kathleen Bloch, Chief Financial Officer, and Chris Cramer, Vice President of Business Development to meet with many analysts and investors.

In addition, CytoSorbents will exhibit at the upcoming Society of Critical Care Medicine (SCCM) 44th Critical Care Congress from January 17-19, 2015 at the Phoenix Convention Center in Phoenix, Arizona. More than 4,000 critical care clinicians from the U.S. and abroad are expected to attend. The Company will be showcasing its CytoSorb® blood purification therapy and discussing with U.S.-based clinicians the various treatment successes to date in critical care medicine, such as in sepsis, influenza, burn injury, trauma, acute lung injury, pancreatitis, liver failure, treatment of post-operative inflammation, and others. CytoSorb® is approved in the European Union and being marketed in 28 countries around the world, but is not yet approved in the United States.

About OneMedForum 2015

OneMedForum 2015 is a leading annual healthcare-focused investor conference bringing together more than 100 presenting growth companies and over 1,300 investors. By connecting companies and investors, the forum helps advance the firms shaping the future of health and medicine. This year, OneMedForum plans to launch OneMedMarket, a marketplace for builders and financiers of healthcare growth companies. Public companies will also be featured on OneMedTV through live streaming of their company presentations as well as the distribution of interviews with CEOs.

About SCCM

The Society of Critical Care Medicine (SCCM) is a non-profit organization that represents nearly 16,000 highly trained professionals in more than 100 countries whose collective goal is to secure the highest quality care for all critically ill and injured patients. The SCCM envisions a day when all such patients are cared for by a dedicated team of physicians, nurses, and other medical professionals specifically trained in critical care. The organization publishes Critical Care Medicine, the premier peer-reviewed, scientific journal in critical care, as well as Pediatric Critical Care Medicine, the first scientific, peer-reviewed journal to focus exclusively on pediatric and neonatal critical care.

The Society of Critical Care Medicine (SCCM) is a non-profit organization that represents nearly 16,000 highly trained professionals in more than 100 countries whose collective goal is to secure the highest quality care for all critically ill and injured patients. The SCCM envisions a day when all such patients are cared for by a dedicated team of physicians, nurses, and other medical professionals specifically trained in critical care. The organization publishes Critical Care Medicine, the premier peer-reviewed, scientific journal in critical care, as well as Pediatric Critical Care Medicine, the first scientific, peer-reviewed journal to focus exclusively on pediatric and neonatal critical care.

About CytoSorbents Corporation

CytoSorbents Corporation is a critical care focused immunotherapy company using blood purification to control severe inflammation -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union and marketed in 28 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2014, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1910667.

Please Click to Follow us on Facebook and Twitter

Contact:

Company Contact
Amy Vogel
CytoSorbents, Inc
Investor Relations
(732) 329-8885 ext. *825
avogel@cytosorbents.com
Investor Contact
Lee Roth
The Ruth Group
(646) 536-7012
lroth@theruthgroup.com
Public Relations Contact
Melanie Sollid-Penton
The Ruth Group
(646) 536-7023
msollid@theruthgroup.com
--------------------------------------------------------------------------------
Source: CytoSorbents Corporation

 
Home | Career Opportunities | Contact Us
© 2014 CytoSorbents Incorporated All Rights Reserved